Inverness Medical Innovations and Beckman Coulter are currently in a bidding war for Biosite and its point of care BNP test. The fight is just one example of the demand for innovative diagnostic test content. The recent upswing in IVD deal-making, along with renewed VC interest in diagnostics, suggests that the area's potential to drive health care innovation by directing therapy more efficiently is finally being recognized.
It’s good times for Biosite Inc. shareholders—and maybe, finally, for
the diagnostics industry as a whole.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
